Prevention of venous thromboembolism with new oral anticoagulants versus standard pharmacological treatment in acute medically ill patients: A systematic review and meta-analysis

Drugs

Volumn 72, Issue 13, 2012, Pages 1755-1764

  Albertsen, Ida Ehlers ^a,b   Larsen, Torben Bjerregaard ^b,c   Rasmussen, Lars Hvilsted ^c   Overvad, Thure Filskov ^a,b   Lip, Gregory Y H ^a,c  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

^c AALBORG UNIVERSITY   (Denmark)

Author keywords

Anticoagulants; Apixaban; Betrixaban; Dabigatran etexilate; Factor Xa inhibitors; Fondaparinux sodium; Low molecular weight heparins; Oral; Rivaroxaban; Venous thromboembolism; Vitamin K antagonists; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; ENOXAPARIN; PLACEBO; RIVAROXABAN;

ACUTE DISEASE; ACUTE DRUG ADMINISTRATION; BLEEDING; CHRONIC DRUG ADMINISTRATION; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; HOSPITAL PATIENT; HUMAN; LUNG EMBOLISM; META ANALYSIS; MORBIDITY; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

ACUTE DISEASE; ADMINISTRATION, ORAL; ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENOXAPARIN; FACTOR XA; HEMORRHAGE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 84865659003     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11635630-000000000-00000     Document Type: Review

References (33)

1. Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141(2 Suppl.):e195S-226S
2. Piazza G, Fanikos J, Zayaruzny M, et al. Venous thromboembolic events in hospitalised medical patients. Thromb Haemost 2009;102(3):505-10
3. Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism. Arch Intern Med 2000;160:809-15
4. Heit JA, O'Fallon MW, Petterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism. Arch Intern Med 2002;162:1245-8 (Pubitemid 34595030)
5. Spencer FA, Lessard D, Emery C, et al. Venous thromboembolism in the outpatient setting. Arch Intern Med 2007;167(14):1471-5 (Pubitemid 47124177)
6. White RH, Zhou H, Romano PS. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost 2003;90:446-55 (Pubitemid 37138770)
7. Stein PD, Henry JW. Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. Chest 1995;108:978-81
8. Lindblad B, Eriksson A, Bergqvist D. Autopsy-verified pulmonary embolism in a surgical department: analysis of the period from 1951 to 1988. Br J Surg 1991;78:849-52
9. Sandler DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? J R Soc Med 1989;82(April): 203-5 (Pubitemid 19086881)
10. National Quality Forum (NQF). National voluntary consensus standards for prevention and care of venous thromboembolism: policy, preferred practices, and initial performance measures. A consensus report. Washington, DC: NQF, 2006
11. Baglin TP, White K, Charles A. Fatal pulmonary embolismin hospitalised medical patients. J Clin Pathol 1997;50:609-18
12. Cohen AT, Tapson VF, Bergmann JF, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 2008;371:387-94 (Pubitemid 351173321)
13. Piazza G, Seddighzadeh A, Goldhaber SZ. Double trouble for 2, 609 hospitalized medical patients who developed deep vein thrombosis: prophylaxis omitted more often and pulmonary embolism more frequent. Chest 2007;132(2):554-61 (Pubitemid 47282388)
14. Guyatt GH, Akl EA, Crowther M, et al. Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141:7S-47S
15. Mousa SA. Oral direct factor Xa inhibitors, with special emphasis on rivaroxaban. Methods Mol Biol 2010;663(1):181-201
16. Davis EM, Packard KA, Knezevich JT, et al. New and emerging anticoagulant therapy for atrial fibrillation and acute coronary syndrome. Pharmacotherapy 2011;31(10):975-1016
17. Duggan ST. Rivaroxaban: a review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery. Am J Cardiovasc Drugs 2012;12(1):57-72
18. Watson J, Whiteside G, Perry C. Apixaban first global approval. Drugs 2011;71(15):2079-89
19. Perzborn E, Roehrig S, Straub A, et al. Rivaroxaban: a new oral factor Xa inhibitor. Arterioscler Thromb Vasc Biol 2010;30:376-81
20. Hull RD, Schellong SM, Tapson VF, et al. Extendedduration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility. Ann Intern Med 2010;153(1):8-18
21. Själander A, Janson J-H, Bergqvist D, et al. Efficacy and safety of anticoagulant prophylaxis to prevent venous thromboembolism in acutely ill medical inpatients: a metaanalysis. J Intern Med 2008;263(1):52-60 (Pubitemid 350243550)
22. Wein L, Wein S, Haas SJ, et al. Pharmacological venous thromboembolism prophylaxis in hospitalized medical patients. Arch Intern Med 2007;167(14):1476-86
23. Goldhaber SZ, Leizorovicz A, Kakkar AK, et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med 2011;365(23):2167-77
24. Cohen AT, Spiro TE, Büller HR, et al. Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. J Thromb Thrombolysis 2011 May; 31:407-16
25. Hughes S. MAGELLAN: rivaroxaban prevents VTE in medical patients, but bleeding is an issue. 2011 [online]. Available from URL: http://www.theheart. org/article/1207331.do [Accessed 6 Feb. 2012]
26. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806-17
27. Granger CB, Alexander JH, McMurray J J V, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92
28. Turpie A G G, Bauer KA, Davidson BL, et al. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). Thromb Haemost 2009;101:68-76
29. Portola Pharmaceuticals. Betrixaban: long-acting, oral, direct factor Xa inhibitor [online]. Available from URL: http://www.portola.com/Betrixaban [Accessed 2012Mar. 21]
30. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008 Jun; 133(6 Suppl.):381-453S
31. Roskell NS, Lip G Y H, Noack H, et al. Treatments for stroke prevention in atrial fibrillation: a network metaanalysis and indirect comparisons versus dabigatran etexilate. Thromb Haemost 2010;104:1106-15
32. Edwards SJ, Clarke MJ, Wordsworth S, et al. Indirect comparisons of treatments based on systematic reviews of randomised controlled trials. Int J Clin Pract 2009;63(6):841-54
33. Bucker HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50(6):683-91(Pubitemid 27341818)